Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL von Friedberg, Jonathan W., Forero-Torres, Andres, Bordoni, Rodolfo E., Cline, Vivian J.M., Patel Donnelly, Dipti, Flynn, Patrick J., Olsen, Gregg, Chen, Robert, Fong, Abraham, Wang, Yinghui, Yasenchak, Christopher A.

Volltext

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E) von Yasenchak, Christopher A., Bordoni, Rodolfo, Patel-Donnelly, Dipti, Larson, Timothy, Goldschmidt, Jerome, Boccia, Ralph V., Cline, Vivian J.M., Mamidipalli, Adrija, Liu, Jingmin, Beck, Joseph T.

Volltext

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients von Yasenchak, Christopher A., Bordoni, Rodolfo, Patel-Donnelly, Dipti, Larson, Timothy, Goldschmidt, Jerome, Boccia, Ralph V., Cline, Vivian J.M., Sacchi, Mariana, Forero-Torres, Andres, Sims, Robert B., Liu, Jingmin, Friedberg, Jonathan W.

Volltext

Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer von Rich, Tyvin A, Winter, Kathryn, Safran, Howard, Hoffman, John P, Erickson, Beth, Anne, Pramila R, Myerson, Robert J, Cline-Burkhardt, Vivian Jm, Perez, Kimberly, Willett, Christopher

Volltext